TCI B6056 (SB-505124) is a selective inhibitor of TGF-β type I receptors (ALK4, ALK5, and ALK7), commonly used as a reference compound in TGF-β/Smad signaling pathway studies. This compound is widely applied in cancer research to investigate tumor cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT), as well as in developmental biology and stem cell research. It is available in 5 mg and 25 mg packaging variants, suitable for in vitro and cell-based assays.
TCI brochures (PDF)
- Organoid Research Reagents 2025-09-11 · p. 7
- Receptor Tyrosine Kinase (RTK) Inhibitors 2026-04-06 · p. 2
- Cancer Research Reagents 2025-04-01 · p. 2
- Immunology Research Reagents 2026-06-03 · p. 9
—
| Brand | — |
|---|---|
| CAS number | — |
| Molecular formula | — |
| Purity | — |
| Category | — |
| Pack sizes | — |
| Physical form | — |
| Storage | — |
—
—

